Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with crohn's disease

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 6, 2013, Pages 667-672

  Seinen, Margien L ^a   Ponsioen, Cyriel Y ^b   de Boer, Nanne K H ^a   Oldenburg, Bas ^c   Bouma, Gerd ^a   Mulder, Chris J J ^a   van Bodegraven, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Crohn's Disease; IBD; Immune Modulation; Inflammatory Bowel Disease; Methotrexate; Retrospective Study

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADOLESCENT; ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; COHORT ANALYSIS; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE SPASM; PATIENT ASSESSMENT; SIDE EFFECT; TREATMENT RESPONSE;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; CROHN DISEASE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878143518     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.12.026     Document Type: Article

References (31)

1. Dignass A. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010, 4:28-62.
2. van Bodegraven A.A., van Everdingen J.J., Dijkstra G., et al. Guideline "Diagnosis and treatment of inflammatory bowel disease in adults". I. Diagnosis and treatment. Ned Tijdschr Geneeskd 2010, 154:A1899.
3. Sokol H., Seksik P., Carrat F., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
4. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
5. Ardizzone S., Bollani S., Manzionna G., et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003, 35:619-627.
6. Maté-Jiménez J., Hermida C., Cantero-Perona J., et al. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000, 12:1227-1233.
7. Chande N., Ponich T., Gregor J. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can J Gastroenterol 2005, 19:553-558.
8. Meuwissen S.G., Ewe K., Gassull M.A., et al. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000, 12:13-18.
9. Kozarek R.A., Patterson D.J., Gelfand M.D., et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989, 110:353-356.
10. Feagan B.G., Fedorak R.N., Irvine E.J., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's study group investigators. N Engl J Med 2000, 342:1627-1632.
11. Feagan B.G., Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am 2004, 33:407-420. xi.
12. Chande N., Abdelgadir I., Gregor J. The safety and tolerability of methotrexate for treating patients with Crohn's disease. J Clin Gastroenterol 2011, 45:599-601.
13. Charpignon C., Beau P. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?. Gastroenterol Clin Biol 2008, 32:153-157.
14. Din S., Dahele A., Fennel J., et al. Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm Bowel Dis 2008, 14:756-762.
15. Domènech E., Mañosa M., Navarro M., et al. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J Clin Gastroenterol 2008, 42:395-399.
16. Fraser A.G., Morton D., McGovern D., et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002, 16:693-697.
17. Hausmann J., Zabel K., Herrmann E., et al. Methotrexate for maintenance of remission in chronic active Crohn's disease: long-term single-center experience and meta-analysis of observational studies. Inflamm Bowel Dis 2010, 16:1195-1202.
18. Lémann M., Zenjari T., Bouhnik Y., et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000, 95:1730-1734.
19. Parker R., Dixit A., Fraser A., et al. Clinical experience of methotrexate in Crohn's disease: response, safety and monitoring of treatment. Postgrad Med J 2010, 86:208-211.
20. Wahed M., Louis-Auguste J.R., Baxter L.M., et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther 2009, 30:614-620.
21. Patel V., Macdonald J.K., McDonald J.W., et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009, 4. CD006884.
22. Suares N.C., Hamlin P.J., Greer D.P., et al. Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. Aliment Pharmacol Ther 2012, 35:284-291.
23. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989, 170:2-6.
24. Satsangi J., Silverberg M.S., Vermeire S., et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
25. Fraser A.G., Orchard T.R., Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002, 50:485-489.
26. Jharap B., Seinen M.L., de Boer N.K., et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010, 16:1541-1549.
27. Klarenbeek N.B., Kerstens P.J., Huizinga T.W., et al. Recent advances in the management of rheumatoid arthritis. BMJ 2010, 341:c6942.
28. Arora S., Katkov W., Cooley J., et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999, 46:1724-1729.
29. Kurnik D., Loebstein R., Fishbein E., et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003, 18:57-63.
30. Oren R., Moshkowitz M., Odes S., et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997, 92:2203-2209.
31. (R)) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial. Scand J Gastroenterol 2012, 47:575-579.